Product image of Midiana (Drospirenone, Ethinylestradiol) supplied by GNH India

Midiana

Active Ingredient:
Drospirenone, Ethinylestradiol
Origin:
EU

Midiana (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Midiana, is a combined oral contraceptive presented as a tablet for oral use. Together with ethinylestradiol, it works to prevent pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age through hormonal regulation of the hypothalamic‑pituitary‑ovarian axis.

GNH India supplies Midiana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Midiana is manufactured in accordance with EU GMP guidelines, ensuring consistent potency and safety for patients.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Midiana, a combined oral contraceptive, is indicated for hormonal contraception and related menstrual disorders.

  • Pregnancy prevention: provides reliable contraception for women of childbearing age.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns.
  • Dysmenorrhea relief: reduces painful menstrual cramps.
  • Acne improvement: may lessen androgen‑dependent acne in some users.
  • Management of heavy menstrual bleeding: contributes to reduced menstrual blood loss.

How It Works

  • Drospirenone and ethinylestradiol bind to progesterone and estrogen receptors, respectively, suppressing the hypothalamic‑pituitary‑ovarian axis. This inhibition prevents the mid‑cycle luteinizing hormone surge, thereby blocking ovulation. In addition, the progestogenic component thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation.

Side Effects

Midiana may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: temporary swelling or soreness.
  • Spotting between periods: irregular light bleeding.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Hypertension: new or worsening high blood pressure.
  • Liver dysfunction: abnormal liver enzyme elevations or jaundice.

Precautions & Warnings

Before prescribing Midiana, clinicians should consider several safety factors.

  • Assess cardiovascular risk: evaluate personal or family history of thrombosis.
  • Avoid smoking: contraindicated in women over 35 who smoke.
  • Monitor blood pressure: check regularly during therapy.
  • Review concomitant medications: consider drugs that affect hepatic enzymes.
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Midiana can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine): may reduce contraceptive efficacy.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase hormone levels and risk of side effects.
  • Anticoagulants (e.g., warfarin): may heighten thrombosis risk.

Moderate Interactions (Monitor Closely)

  • Rifampin and other potent antibiotics: may lower contraceptive effectiveness.
  • St. John’s wort (herbal supplement): may decrease hormone concentrations.
  • Thiazide diuretics: may affect blood pressure control while on the pill.

Frequently Asked Questions

Midiana is a combined oral contraceptive indicated primarily for preventing unintended pregnancy in women of reproductive age. It is also prescribed to help regulate menstrual cycles, reduce heavy bleeding, and may improve acne associated with hormonal fluctuations.

The two hormones act together to suppress the hypothalamic‑pituitary‑ovarian axis, preventing the surge of luteinizing hormone that triggers ovulation. Drospirenone also thickens cervical mucus and alters the endometrium, creating conditions that are unfavorable for fertilization and implantation.

The dosing regimen for Midiana is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time for a 21‑day active cycle followed by a hormone‑free interval, but the exact schedule should follow the prescriber’s instructions.

Midiana is contraindicated in pregnancy (Category X) and should not be started or continued if a woman becomes pregnant. While limited data exist for breastfeeding, most guidelines advise caution; alternative contraception is usually recommended for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midiana contains drospirenone, a progestin with anti‑androgenic and mild diuretic properties, which can offer benefits such as reduced water retention and potential acne improvement. Compared with older progestins, it may have a slightly different side‑effect profile, but overall contraceptive efficacy is comparable across approved combined pills.

Midiana tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children. Do not use tablets that appear discolored or damaged.

Midiana is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and should be taken with or without food, as directed by the prescriber. Consistent daily intake maximizes contraceptive effectiveness.

The most serious risks include venous thromboembolism (blood clots), arterial thrombosis (stroke or heart attack), and hypertension. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid using Midiana.

Midiana is contraindicated in women who are pregnant, have known or suspected thromboembolic disease, uncontrolled hypertension, active liver disease, or a history of estrogen‑dependent tumors. It is also not recommended for smokers over 35 years of age and for individuals with known hypersensitivity to drospirenone, ethinylestradiol, or any tablet excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT